Zacks Investment Research on MSN
Hims & Hers expands weight-management program to the United Kingdom
Hims & Hers HIMS recently announced that it is expanding access to its comprehensive Weight Loss Program to customers in the ...
Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo Nordisk’s ...
Zacks Investment Research on MSN
Hims & Hers expands its technology-driven personalized virtual care
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates as a deeply technology-driven digital ...
The trajectory of well-known health and wellness platform Hims & Hers is one that most entrepreneurs and investors would hope for. Not even six years old, the company has for the most part experienced ...
The market is just starting to notice the great things this small-cap stock has been doing for a while now. It often feels like you've missed the boat when you sit there reading about another stock ...
The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...
Medical Device Network on MSN
Hims & Hers Health signs agreement to acquire YourBio Health
Hims & Hers Health has signed a definitive agreement to acquire US-based YourBio Health, which provides capillary blood ...
Hims and Hers first announced its expansion into Canada in early July, taking the opportunity as Danish pharmaceutical giant ...
Health platform Hims & Hers Health Inc. announced Monday that it's rolling out injectable weight-loss drugs that cost a fraction of the price of competitors Wegovy and Ozempic. Hims & Hers says its ...
Online health and wellness company Hims & Hers bumped its full-year revenue forecast higher following strong growth in subscribers and double-digit net income in the first quarter. The company, which ...
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth ...
Eli Lilly and Co (NYSE:LLY) today announced an expansion in the availability of its obesity treatment, Zepbound (tirzepatide), which is now offered in 2.5 mg and 5 mg single-dose vials at a discounted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback